Transactions

Transactions

  • Tilray intends to use the net proceeds for working capital, future acquisitions and general corporate purposes, and to repay the existing mortgage related to their facility in Nanaimo, British Columbia.
  • Guardant Health, Inc. is a leading molecular diagnostics company focused on enabling precision medicine through use of its proprietary blood-based assays, focused in the emerging liquid biopsy arena. The Company’s core Health Oncology Platform is designed to improve patient clinical outcomes, lower healthcare costs, and accelerate biopharmaceutical drug development to manage cancer across all stages of the disease.
  • Twist is a leading and rapidly growing synthetic biology company that has developed a disruptive, scalable DNA synthesis platform targeted at diverse end markets. The core of Twist’s platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA
  • Founded in 2003, REVOLVE is a leading e-commerce retailer serving the fashion-savvy millennial and Gen-Z consumer. The Company offers curated collections as well as style recommendations and content generated by both REVOLVE and users. The Company has two platforms: REVOLVE and FORWARD by Elyse Walker.
  • NGM Bio is a clinical-stage biopharmaceutical company with a drug discovery approach that is currently focused on key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases
  • PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary diseases.
  • Farfetch is the leading technology platform for the global luxury fashion industry. The Company operates the only truly global luxury digital marketplace at scale, seamlessly connecting brands, retailers and consumers
  • Y-mAbs Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad, advanced product pipeline, including two pivotal-stage candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively
  • Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor Tcell (CAR T) therapies for cancer.
  • Cision Ltd. (NYSE: CISN) is a leading global provider of PR software, media distribution, media intelligence and related professional services. Public relations and communications professionals use its products and services to help manage, execute and measure their strategic PR and communications programs.
  • Cowen is pleased to announce that Draper Oakwood Technology Acquisition, Inc. and Reebonz Limited (“Reebonz”), a leading online luxury marketplace and platform in the Asia Pacific region based in Singapore, announced today that they have entered into a definitive business combination agreement pursuant to which DOTA and Reebonz will become subsidiaries of a newly created Cayman Islands exempted company, DOTA Holdings Limited (“RBZ”).
  • Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on leveraging its cell-free protein synthesis platform, XpressCF, to create a broad variety of complex, next-generation protein therapeutics for oncology.
1 2 3 4 ...84 Next